



## Darktrace Antigena Email — Cyber Catalyst 2020 Designation

Antigena Email is a self-learning technology that neutralizes targeted email campaigns and impersonation attacks that evade an organization's email gateway. Powered by Darktrace's core AI, Antigena Email technology "understands the human" in the context of dynamic relationships and communication patterns. This enables the system to intelligently determine whether a given email meaningfully deviates from normal interactions between sender, recipient, and the wider organization, instantly revealing the subtle signs of a novel threat.

Advanced email attacks that leverage social engineering, fresh domains, compromised accounts, and novel strains of malware routinely get past static email defenses, which apply preset rules or rely on blacklists of "known bad" domains and IP addresses. These defenses can only detect historical attack techniques that get reused in the future, and therefore can't anticipate novel types of attacks.

Antigena Email takes a more nuanced approach, asking not whether an incoming email or associated element or technique has been observed historically, but crucially whether the email belongs – right here, right now, in the context of the normal "patterns of life" of dynamic human behaviors and relationships.

It does this through self-learning artificial intelligence, updating itself continuously as the business and workforce evolve. It neutralizes targeted email attacks by learning "normal" patterns of behavior in email traffic, and spotting subtle deviations indicative of a threat. By analyzing inbound, outbound, and lateral email traffic, the technology learns normal "on the job" without relying on rules, blacklists, whitelists, signatures, historical attack data, or prior assumptions of any kind. This self-learning approach differentiates Antigena Email and enables it to catch targeted emails attacks such as advanced spear phishing, Business Email Compromise, social engineering, spoofing and solicitation, supply chain account takeover, and outbound data loss detection.

Antigena Email is cloud native and can be installed in minutes. It is suitable for any size or type of organization and facilitates hands-off oversight by the security and/or IT team. A high-level risk dashboard also presents trends over time and furnishes an at-a-glance overview for non-technical executives.

*\*Product information provided by Darktrace*

For more information about Darktrace Antigena Email, visit <https://www.darktrace.com/en/products/antigena-email/>

## Why Darktrace Antigena Email is a 2020 Cyber Catalyst Designated Solution

### ADDRESSES A TOP 5 CYBER RISK:

The 2020 program encouraged the submission of solutions that targeted the top five cyber risks identified by participating insurers: ransomware, supply chain/vendor management, cloud migration/management, social engineering, and privacy regulation/data management.

Darktrace Antigena Email specifically targets social engineering, but also has wider utility and applicability in addressing other types of cyber risk.

### INSURER RATINGS AND COMMENTARY:

Cyber Catalyst participating insurers rated Darktrace Antigena Email highest on the criteria of cyber risk reduction, flexibility, and efficiency.

In their evaluation, the insurers commented:

- “A very novel context-based approach that asks not whether an incoming email is malicious but crucially whether it belongs – clearly valuable for organizations.”
- “In terms of email security, this seems to be one of the best. Clean user interface and of great assistance for large attack vectors that could cause loss. Platform apparently requires minimal monitoring and intervention, and presumably becomes more useful with increasing use.”
- “This is a good email solution to help detect and highlight anomalous behavior, reduce the risk of fraud, and prevent phishing and other email-based attacks that could gain a foothold into the organization.”

## Insurance Policies and Implementation Principle

Organizations that adopt Cyber Catalyst designated solutions may be considered for enhanced terms and conditions on individually negotiated cyber insurance policies with participating insurers.

Those insurers, when considering potential policy enhancements, will expect organizations to deploy Cyber Catalyst designated products and services in accordance with certain “implementation principles” that have been developed by the insurers and product vendors.

The implementation principle for Darktrace Antigena Email is:

- The product is deployed on 100% of email domains.

## Evaluation Process

Applications for evaluation of cybersecurity products and services were accepted from March 10 to May 15, 2020. More than 90 offerings, spanning a broad range of categories, were submitted.

The insurers evaluated eligible solutions along six criteria:

1. Reduction of cyber risk.
2. Key performance metrics.
3. Viability.
4. Efficiency.
5. Flexibility.
6. Differentiation.

Cyber Catalyst designation was awarded to solutions receiving positive votes from at least six of the eight insurers, which voted independently. Marsh did not participate in the Cyber Catalyst designation decisions.

## More Information on Cyber Catalyst

The next Cyber Catalyst program will occur in 2021.

For more information on the 2020 Cyber Catalyst designated solutions, or the 2019 class of Cyber Catalyst solutions, visit the Cyber Catalyst pages on the Marsh website: [www.marsh.com/cybercatalyst](http://www.marsh.com/cybercatalyst).

For more information about Marsh’s cyber risk management solutions, email [cyber.risk@marsh.com](mailto:cyber.risk@marsh.com), visit [www.marsh.com](http://www.marsh.com), or contact your Marsh representative.

Marsh is one of the Marsh & McLennan Companies, together with Guy Carpenter, Mercer, and Oliver Wyman.

This document and any recommendations, analysis, or advice provided by Marsh (collectively, the “Marsh Analysis”) are not intended to be taken as advice regarding any individual situation and should not be relied upon as such. The information contained herein is based on sources we believe reliable, but we make no representation or warranty as to its accuracy. Marsh shall have no obligation to update the Marsh Analysis and shall have no liability to you or any other party arising out of this publication or any matter contained herein. Any statements concerning actuarial, tax, accounting, or legal matters are based solely on our experience as insurance brokers and risk consultants and are not to be relied upon as actuarial, tax, accounting, or legal advice, for which you should consult your own professional advisors. Any modeling, analytics, or projections are subject to inherent uncertainty, and the Marsh Analysis could be materially affected if any underlying assumptions, conditions, information, or factors are inaccurate or incomplete or should change. Marsh makes no representation or warranty concerning the application of policy wording or the financial condition or solvency of insurers or reinsurers. Marsh makes no assurances regarding the availability, cost, or terms of insurance coverage. Although Marsh may provide advice and recommendations, all decisions regarding the amount, type or terms of coverage are the ultimate responsibility of the insurance purchaser, who must decide on the specific coverage that is appropriate to its particular circumstances and financial position.

Copyright ©2020 Marsh LLC. All rights reserved. MA20-XXXXX 616302668